Use of arsentic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) .1. Arsenic causes both apoptosis and partial differentiation of NB4 and fresh APL cells in vitro and in vivo

被引：0
|
作者：
Chen, Z
Chen, GO
Shi, XG
Tang, W
Zhu, J
Xiong, SM
Ni, IH
Gazin, C
Waxman, S
Wang, ZY
Chen, SJ
机构：
[1] SHANGHAI MED UNIV 2,RUI JIN HOSP,SHANGHAI INST HEMATOL,SHANGHAI,PEOPLES R CHINA
[2] HOP ST LOUIS,PARIS,FRANCE
[3] MT SINAI MED CTR,NEW YORK,NY 10029
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：864 / 864
页数：1
相关论文
共 42 条
  • [21] GM-CSF and arsenic trioxide (As2O3) induce differentiation, but not apoptosis, of retinoic acid (RA)-resistant APL in vitro and in vivo by modulating Jak2 tyrosine kinase and BAX.
    Muto, A
    Kizaki, M
    Fukuchi, Y
    Kinjo, K
    Ikeda, Y
    BLOOD, 1998, 92 (10) : 510A - 510A
  • [22] Arsenic trioxide (AS2O3) therapy for relapsed acute promyelocytic leukemia (APL):: Comparison with a historic control combining all-traps retinoic acid (ATRA) plus intensive chemotherapy
    Thomas, X
    Pigneux, A
    Raffoux, E
    Huguet, F
    Caillot, D
    Guerci, A
    Stamatoullas, A
    Reman, O
    Isnard, F
    Dreyfus, F
    Gratecos, N
    Bernard, M
    Arkam, Y
    Fenaux, P
    BLOOD, 2005, 106 (11) : 263A - 263A
  • [23] Clinical study of combining arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and idarubicin (IDA) for induction therapy on the patients with relapsed acute promyelocytic leukemia(APL)
    Ma, J.
    Liu, J.
    Zhang, B.
    Zhan, Z.
    Jin, M.
    Wang, L.
    Gong, T.
    Shao, X.
    EJC SUPPLEMENTS, 2005, 3 (02): : 284 - 284
  • [24] Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL).
    Tsirriberidou, A. M.
    Kantarjian, H. M.
    Garcia-Manero, G.
    Koller, C.
    Jones, D. M.
    Keating, M. J.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S
  • [25] Comparison of uptake and intracellular induced structural changes of arsenic trioxide, an inorganic compound, and organic arsenic derivative S-dimethylarsino-glutathione (SGLU; ZIO-101) in NB4 acute promyelocytic leukemia (APL) cells.
    Manshouri, T
    Kala, SV
    Ashoori, F
    Zingaro, R
    Freireich, EJ
    Andreeff, M
    Kantarjian, HM
    Verstovsek, S
    BLOOD, 2005, 106 (11) : 190B - 190B
  • [26] All-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy induces high rates of durable molecular remission in newly diagnosed acute, promyelocytic leukemia (APL)
    Tsimberidou, Apostolia-Maria
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Koller, Charles
    Jones, Daniel
    Pierce, Sherry
    Brandt, Mark
    Keating, Michael
    Estey, Estey
    BLOOD, 2007, 110 (11) : 543A - 543A
  • [27] A 3-year follow-up of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL)
    Hu, J
    Liu, YF
    Zhu, YM
    Shi, ZZ
    Li, JM
    Wang, L
    Chen, Y
    Shen, ZX
    BLOOD, 2005, 106 (11) : 260A - 260A
  • [28] Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia
    A Habib
    E Hamade
    R Mahfouz
    M S Nasrallah
    H de Thé
    A Bazarbachi
    Leukemia, 2008, 22 : 1125 - 1130
  • [29] ARSENIC TRIOXIDE INHIBITS ATRA-INDUCED PROSTAGLANDIN E2 AND CYCLOOXYGENASE-1 IN NB4 CELLS, A MODEL OF ACUTE PROMYELOCYTIC LEUKEMIA
    Bazarbachi, A.
    Habib, A.
    Hamade, E.
    Mahfouz, R.
    Nasrallah, M.
    De The, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 451 - 451
  • [30] Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia
    Habib, A.
    Hamade, E.
    Mahfouz, R.
    Nasrallah, M. S.
    de The, H.
    Bazarbachi, A.
    LEUKEMIA, 2008, 22 (06) : 1125 - 1130
12345